A few years ago, Pfizer (PFE +0.51%) looked unstoppable. The company generated more than $100 billion in annual revenue early ...
Arvinas and Pfizer to receive $85 million in upfront and transition payments with potential for additional $320 million in development, ...
Pfizer and Arvinas have landed a buyer for the newly approved breast cancer med Veppanu, selling an exclusive global license to Rigel Pharmaceuticals for $85 million upfront and potentially hundreds ...
Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) just closed the books on Q4 2025, and the contrast is striking. Pfizer leaned on ...
By Mariam Sunny and Christy Santhosh May 5 (Reuters) - Pfizer said on Tuesday that it expects to return to stronger growth ...
Pfizer's acquired and recently launched products generated strong growth last quarter.
An indirect comparison highlights Attruby’s potential as the better TTR stabiliser over Pfizer’s tafamidis in frontline ATTR-CM.
Pfizer Inc. PFE on Tuesday reported better-than-expected first-quarter results and reaffirmed its 2026 financial guidance.
The Motley Fool on MSN
Is Pfizer's 6% Dividend Yield Safe? Here's What Investors Need to Know.
Pfizer's vaccine business cooled off, and it is on its back foot in the GLP-1 race, but don't count the drug giant out.
Washington — Pfizer has agreed to offer significantly discounted prices for some prescription drugs for all American consumers and has committed to offer prescription medications to Medicaid at lower ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results